- Home
- FBIO vs ANTX Comparison
FBIO vs ANTX Comparison
Compare FBIO & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBIO
- ANTX
- Stock Information
- Founded
- FBIO 2006
- ANTX 2017
- Country
- FBIO United States
- ANTX United States
- Employees
- FBIO N/A
- ANTX N/A
- Industry
- FBIO Biotechnology: Pharmaceutical Preparations
- ANTX Biotechnology: Pharmaceutical Preparations
- Sector
- FBIO Health Care
- ANTX Health Care
- Exchange
- FBIO Nasdaq
- ANTX Nasdaq
- Market Cap
- FBIO 39.4M
- ANTX 40.0M
- IPO Year
- FBIO N/A
- ANTX 2022
- Fundamental
- Price
- FBIO $1.83
- ANTX $1.36
- Analyst Decision
- FBIO Strong Buy
- ANTX Hold
- Analyst Count
- FBIO 3
- ANTX 5
- Target Price
- FBIO $18.00
- ANTX $3.50
- AVG Volume (30 Days)
- FBIO 691.0K
- ANTX 933.0K
- Earning Date
- FBIO 11-14-2024
- ANTX 11-13-2024
- Dividend Yield
- FBIO N/A
- ANTX N/A
- EPS Growth
- FBIO N/A
- ANTX N/A
- EPS
- FBIO N/A
- ANTX N/A
- Revenue
- FBIO $81,501,000.00
- ANTX N/A
- Revenue This Year
- FBIO N/A
- ANTX N/A
- Revenue Next Year
- FBIO $134.70
- ANTX N/A
- P/E Ratio
- FBIO N/A
- ANTX N/A
- Revenue Growth
- FBIO 31.51
- ANTX N/A
- 52 Week Low
- FBIO $1.36
- ANTX $0.87
- 52 Week High
- FBIO $4.43
- ANTX $22.22
- Technical
- Relative Strength Index (RSI)
- FBIO 49.60
- ANTX 50.02
- Support Level
- FBIO $1.78
- ANTX $1.32
- Resistance Level
- FBIO $2.27
- ANTX $1.59
- Average True Range (ATR)
- FBIO 0.17
- ANTX 0.09
- MACD
- FBIO -0.03
- ANTX -0.03
- Stochastic Oscillator
- FBIO 21.43
- ANTX 7.89
About FBIO Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.